Home Cart Sign in  
Chemical Structure| 1314891-22-9 Chemical Structure| 1314891-22-9

Structure of TMP195
CAS No.: 1314891-22-9

Chemical Structure| 1314891-22-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TMP195 is an inhibitor of class IIa histone deacetylase (HDAC) with IC50 of 15 nM - 59 nM for HDAC4, 5, 7 and 9.

Synonyms: TFMO 2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TMP195

CAS No. :1314891-22-9
Formula : C23H19F3N4O3
M.W : 456.42
SMILES Code : O=C(NCC(C1=COC(C2=CC=CC=C2)=N1)(C)C)C3=CC=CC(C4=NOC(C(F)(F)F)=N4)=C3
Synonyms :
TFMO 2
MDL No. :MFCD26522024
InChI Key :QTCSXAUJBQZZSN-UHFFFAOYSA-N
Pubchem ID :67324851

Safety of TMP195

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of TMP195

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC4

    HDAC4, Ki:59 nM

  • HDAC9

    HDAC9, Ki:15 nM

  • HDAC7

    HDAC7, Ki:26 nM

  • HDAC5

    HDAC5, Ki:60 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BMDMs 40 μM 2 hours TMP195 promoted M1 polarization of BMDMs and increased the release of inflammatory cytokines PMC9576521
Primary mouse astrocytes 1 μM 4 hours To investigate the effects of TMP195 on tau uptake and degradation in astrocytes, results showed that TMP195 treatment significantly enhanced tau uptake and lysosomal trafficking. PMC11727263
HK-2 cells 5 μM 48 hours TMP195 alleviated the loss of epithelial phenotype and downregulated proinflammatory mediators in HK-2 with AA treatment, inhibiting G2/M cell cycle arrest. PMC10212923
Human macrophages 10 µM 48 hours TMP195 significantly reduced the growth of Mtb in macrophages, particularly in Mφ2. PMC7008710
Human monocytes 300 nM 5 days TMP195 enhanced the ability of monocytes to differentiate into antigen presenting cells and promoted T cell co-stimulatory function. PMC8170529
Bone Marrow Mononuclear Macrophages (BMMs) 20 µg/mL 6 days To evaluate the effect of TMP195 on the differentiation of BMMs into osteoclasts, results showed that mPPTMP195 inhibited osteoclast differentiation more effectively than free TMP195. PMC11100250
Monocytes 300 nM 6 days TMP195 enhanced the bactericidal capacity of macrophages during monocyte differentiation. PMC7008710
Bone Marrow Mesenchymal Stem Cells (BMSCs) 20 µg/mL 7 days To evaluate the effect of TMP195 on the differentiation of BMSCs into osteoblasts, results showed that mPPTMP195 promoted osteogenic differentiation more effectively than free TMP195. PMC11100250
KB-3-1 cells 1 μM, 2 μM, 3 μM, 5 μM 72 hours TMP195 significantly resensitized ABCB1-overexpressing multidrug-resistant cells to paclitaxel in a concentration-dependent manner, without affecting the cytotoxicity of paclitaxel in drug-sensitive parental cells. PMC6981391
KB-V-1 cells 1 μM, 2 μM, 3 μM, 5 μM 72 hours TMP195 significantly resensitized ABCB1-overexpressing multidrug-resistant cells to paclitaxel in a concentration-dependent manner, without affecting the cytotoxicity of paclitaxel in drug-sensitive parental cells. PMC6981391
S1-M1-80 cells 1 μM, 2 μM, 3 μM, 5 μM 72 hours TMP195 reversed ABCG2-mediated resistance to mitoxantrone in S1-M1-80 cells. PMC6981391
MC38 cells 5 μM, 20 μM, 40 μM, 60 μM TMP195 had no significant effect on MC38 cell proliferation or apoptosis PMC9576521

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MMTV-PyMT transgenic mice Intraperitoneal injection 50 mg/kg Daily for 13-24 days TMP195 modulates macrophage phenotype, reduces tumor burden and pulmonary metastases, and enhances the efficacy of chemotherapy and immune checkpoint blockade. PMC8170529
Mice PS19 mice Intraperitoneal injection 50 mg/kg Every 3 days for 2 months To investigate the effects of TMP195 on tau pathology, synaptic plasticity, and cognitive function in PS19 mice, results showed that TMP195 significantly improved tau pathology, synaptic impairments, and cognitive deficits. PMC11727263
C57BL/6 mice AAN (aristolochic acid nephropathy) model Intraperitoneal injection 50 mg/kg Once daily for 4 weeks TMP195 alleviated tubular atrophy and tubulointerstitial fibrosis in AAN mice, reduced inflammatory responses, and inhibited G2/M phase cell cycle arrest. PMC10212923
Mice Femur Fracture Model Local Subcutaneous Injection 20 µg/mL Every other day for a total of four injections To evaluate the effect of mPPTMP195 on fracture healing, results showed that mPPTMP195 promoted fracture healing more effectively than free TMP195. PMC11100250
Zebrafish embryos Mycobacterium marinum infection model In egg water 10 µM 24 hours TMP195 significantly reduced the mycobacterial infection burden in zebra?sh embryos. PMC7008710
C57BL/6 mice Colitis-associated colorectal cancer model intraperitoneal injection 50 mg/kg/day daily for 28 days TMP195 significantly reduced the tumor burden in the CAC model PMC9576521
Mice xenograft mouse model of KMT2A-rearranged ALL intraperitoneal injection 50 mg/kg/day 5 times a week for a total of 15 days TMP195 failed to show anti-leukemic effects at the maximum tolerable dose, and the experiment was terminated early. PMC11450098

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.95mL

2.19mL

1.10mL

21.91mL

4.38mL

2.19mL

References

 

Historical Records

Categories